N62 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM N62 became effective on October 1, 2020. This is the American ICD-10-CM version of N62 - other international versions of ICD-10 N62 may differ. Applicable To. Gynecomastia.
Benign Gynecomastia: The development of abnormally large breasts in males. It is related to the excess growth of breast tissue (glandular), rather than excess fat tissue. Congenital Anomaly: A physical developmental defect that is present at the time of birth, and that is identified within the first twelve months of birth. (2011 Generic COC)
Gynecomastia can be typically classified into four grades of increasing severity, from I to IV,[13] ranging from simple areolar protrusion, to breasts with a female appearance.[13]
The early stages of gynecomastia are characterized by ductal epithelial hyperplasia (the proliferation and lengthening of the ducts), increases in stromal and periductal connective tissue, increased periductal inflammation, intensive periductal edema and stromal fibroblastic proliferation.
The 2022 edition of ICD-10-CM N63. 0 became effective on October 1, 2021. This is the American ICD-10-CM version of N63.
A disorder characterized by marked discomfort sensation in the breast region. Pain in the breast generally classified as cyclical (associated with menstrual periods), or noncyclical, i.e. Originating from the breast or nearby muscles or joints, ranging from minor discomfort to severely incapacitating.
N62: Hypertrophy of breast.
ICD-10 code N64. 4 for Mastodynia is a medical classification as listed by WHO under the range - Diseases of the genitourinary system .
For example, Z12. 31 (Encounter for screening mammogram for malignant neoplasm of breast) is the correct code to use when you are ordering a routine mammogram for a patient.
Mastodynia is the medical term describing the common symptom of breast pain, also labeled as mastalgia. This symptom can occur in both men and women, but it presents more often in women, with the severity of the pain varying from mild and self-limited to severe pain.
ICD-10 DiagnosisICD-10 DiagnosisN62Hypertrophy of breast (gynecomastia)Q98.0-Q98.4Klinefelter's syndromeZ79.51-Z79.52Long-term (current) use of steroidsZ79.818Long term (current) use of other agents affecting estrogen receptors and estrogen levels3 more rows
N62 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM N62 became effective on October 1, 2021.
Gynecomastia is a benign enlargement of the male breast (usually bilateral but sometimes unilateral) resulting from a proliferation of the glandular component of the breast (see the image below). It is defined clinically by the presence of a rubbery or firm mass extending concentrically from the nipples.
2022 ICD-10-CM Diagnosis Code N63: Unspecified lump in breast.
ICD-10 code R92. 8 for Other abnormal and inconclusive findings on diagnostic imaging of breast is a medical classification as listed by WHO under the range - Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified .
In men, breast pain is most commonly caused by a condition called "gynecomastia" (guy-nuh-koh-MAS-tee-uh). This refers to an increase in the amount of breast gland tissue that's caused by an imbalance of the hormones estrogen and testosterone. Gynecomastia can affect one or both breasts, sometimes unevenly.
This article has been cited byother articles in PMC. Abstract. Gynecomastia is the benign enlargement of male breast glandular tissue and is the most common breast condition in males. At least 30% of males will be affected during their life. Since it causes anxiety, psychosocial discomfort and fear of breast cancer, ...
The early stages of gynecomastia are characterized by ductal epithelial hyperplasia (the proliferation and lengthening of the ducts), increases in stromal and periductal connective tissue, increased periductal inflammation, intensive periductal edema and stromal fibroblastic proliferation.
Because of the increasing incidence of obesity, the number of patients with pseudogynecomastia is increasing. In addition, increased use of anabolic steroids and environmental contamination with xenoestrogens or estrogen-like substances may stimulate glandular proliferation in male breast tissue.[10] . In mild cases, simple reassurance coupled ...
The duration of gynecomastia is a major factor affecting the initial approach to treatment. In the early stages, ductal hyperplasia and periductal inflammation are common and this is also the most symptomatic and treatable stage. In cases of over 12m' duration, fibrosis occurs, while inflammation subsides.
Pubertal gynecomastia usually begins at age 10-12-years-old and peaks at ages 13-14. It usually regresses within 18m and is uncommon in males aged 17 and older.[8,11] The final peak occurs in older males (particularly in those aged 50-80-years-old), with a prevalence of 24-65%.
Medications have been reported to cause up to 25% of cases of gynecomastia and they can be categorized by their hormone-like action.[6,10] Type 1 medications act like estrogens and include diethylstilbestrol (DEB), oral contraceptives, phytoestrogens, digitalis and estrogen-containing cosmetics.
Finally, tumors can lead to gynecomastia due to increased aromatase activity in the tumor itself.[4] Starvation. Malnourishment can cause gynecomastia due to decreased gonadotropin and T levels, coupled with normal production of estrogen s ( and their precursors) from the adrenal glands.[11] .
In most cases breast enlargement and/or benign gynecomastia spontaneously resolves by age 18 making treatment unnecessary. Gynecomastia during puberty is not uncommon and in 90% of cases regresses within 3 years of onset.
I. Mastectomy or suction lipectomy for treatment of benign gynecomastia for a male patient under age 18 is considered reconstructive and medically necessary when all the following criteria are met: